Business
Canopus BioPharma Inc. Announces Results from Compassionate Study in Hepatitis C patients in China
Canopus BioPharma Inc. Announces Results from Compassionate Study in Hepatitis C patients in China.
About this update from Canopus Biopharma, Inc.
[{"type":"text","content":"\n\n\n\nCanopus BioPharma Inc. Announces Results from Compassionate Study in Hepatitis C patients in China\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nCanopus BioPharma Inc. Announces Results from Compassionate Study in Hepatitis C patients in China\n- Results Confirm Efficacy and Safety of an All-Oral combination of Mogrovir™ with Ribavirin™ in Genotype 1, Therapy Naive HCV Patients.\nPR Newswire\nLOS ANGELES, July 1, 2014\n\n\n\nLOS ANGELES, July 1, 2014 /PRNewswire/ -- Canopus BioPharma Inc. (OTC Pink: CBIA) today announced topline results from a Compassionate Clinical Trial in China, evaluating the twice daily oral administration of Mogroside IV (Mogrovir™).  Mogrovir™ is a Toll-like receptor agonist and stimulator of the patient's immune system. Mogrovir™ was administered orally in combination with Ribavirn (RBV), for the treatment of Genotype 1, treatment naive Hepatitis C (HCV) patients. The study showed a statistically significant result regarding the improvement of both liver function and increased blood platelet counts.  A selection of patients in the trial also showed a statistically significant reduction in HCV viral-load levels, in the three month follow up period post-therapy. HCV Viral-load in these specific patients were approaching zero after a period of 180 days (90 days Mogrovir™ Treatment and 90 days follow-up). This fact confirmed the immune activation effects which are expected from the immune activation characteristics of Mogrovir™.\n\nChina has one of the highest rates of liver cancer of any industrialized country and the majority of cases are due to chronic HCV infection.  An estimated 36 million people in China are living with HCV infection and approximately 34-38 percent have the Genotype-1 strain of the Virus. Genotype-1 HCV is currently the most resistant of the HCV strains to conventional anti-viral treatments. \n\nTwenty eight  patients were enrolled in the Canopus BioPharma study and all patients completed the study, without any toxicity or negative side-effects being docume...